#China #Chengdu #radiopharmaceuticals #C-Ray Therapeutics #AAALAC International

C-Ray Therapeutics Earns Prestigious AAALAC Accreditation

C-Ray Therapeutics, a leading entity in the field of radiopharmaceuticals, has recently announced that it has received Full Accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). This accolade represents a significant milestone for the company, reinforcing its unwavering commitment to ethical and quality-driven preclinical research practices.

Significance of AAALAC Accreditation

AAALAC International serves as a globally recognized authority dedicated to promoting excellence in laboratory animal care. The organization’s voluntary accreditation program assesses institutions based on stringent international guidelines and practices regarding animal care and use in research. Achieving Full Accreditation signifies that C-Ray Therapeutics not only meets but exceeds basic compliance standards, showcasing exceptional practices in animal care, innovative quality management systems, and comprehensive adherence to ethical regulations.

The rigorous evaluation process involved comprehensive on-site inspections, meticulous reviews of documentation, and thorough verification of compliance with respected guidelines, including the Guide for the Care and Use of Laboratory Animals.

Impact on Preclinical Research

Haitao Qiao, the General Manager of C-Ray Therapeutics, expressed that achieving this accreditation is more than just a compliance milestone; it serves as a crucial facilitator for clients seeking efficient preclinical research pathways. Biotechnology firms engaged in developing innovative radiopharmaceuticals can now conduct their preclinical operations confidently in China, knowing that the data generated will satisfy Western regulatory standards. In a field often characterized by lengthy timelines, C-Ray's unique Investigator-Initiated Trials (IIT) framework can significantly reduce development times, enabling researchers to access first-in-human data within six to nine months, compared to over 24 months using traditional methods.

Outstanding Facility and Capabilities

C-Ray’s integrated facility, spanning 28,000 square meters, is equipped with state-of-the-art infrastructures, combining AAALAC-accredited preclinical capabilities with certified Good Manufacturing Practices (cGMP). It holds China's Class A Radiation Safety License, the highest tier, allowing it to work with over 30 radioisotopes, including complex alpha-emitters like Actinium-225.

To date, the company has successfully completed more than 70 Contract Research, Development and Manufacturing Organization (CRDMO) projects, including 50 focused on preclinical and molecular imaging services and 24 dedicated to clinical supply development. Among these projects, C-Ray Therapeutics has adeptly facilitated five programs through Investigational New Drug (IND) stages, enabling 16 investigator-initiated trials, and provided clinical supplies for three programs, two of which are progressing to Phase III clinical studies.

Strengthening Global Partnerships

As C-Ray Therapeutics continues to expand its global footprint, the AAALAC accreditation addresses a crucial barrier for Western partners looking to leverage China's competitive advantages in speed and costs, while requiring assurance of ethical standards and quality. Qiao reiterated their commitment to delivering both expedience and high quality, ensuring that clientsare not forced to compromise on their standards for the sake of speed.

With an impressive $187 million raised thus far, C-Ray is well-positioned to continue its investment in infrastructure, isotope supply chain partnerships, and regulatory expertise, reinforcing its role in the global radiopharmaceutical community.

In conclusion, C-Ray Therapeutics' achievement of Full Accreditation from AAALAC International is a testament to its dedication to ethical research standards and its ongoing mission to support innovation within the pharmaceutical industry, particularly in the promising sector of radiopharmaceuticals.